 |
 |
Sunderland Joint Formulary
NHS Sunderland Clinical Commissioning Group South Tyneside and Sunderland NHS Foundation Trust |
Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Useful Links |
NICE TA 539: Neuroendocrine tumours (metastatic, unresectable, progressive) - 177 Lu-dotatate |
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
08.01 |
Cytotoxic drugs (0,0)
|
|

Side-effects of cytotoxic drugs
(0,1)
|
|

Drugs for cytotoxic-induced side-effects
(5,4)
|
08.01.01 |
Alkylating drugs
(11,0)
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(10,0)
|
08.01.03 |
Antimetabolites
(12,5)
|
08.01.04 |
Vinca alkaloids and etoposide
(5,0)
|
08.01.05 |
Other antineoplastic drugs
(33,5)
|
|

Amsacrine
(1,0)
|
|

Arsenic trioxide
(1,0)
|
|

Bevacizumab
(1,0)
|
|

Bexarotene
(0,1)
|
|

Bortezomib
(1,0)
|
|

Brentuximab vedotin
(1,0)
|
|

Cetuximab
(1,0)
|
|

Crisantaspase
(0,1)
|
|

Dacarbazine and Temozolomide
(3,0)
|
|

Erlotinib
(1,0)
|
|

Hydroxycarbamide
(1,0)
|
|

Imatinab (0,0)
|
|

Ipilimumab
(1,0)
|
|

Mitotane
(1,0)
|
|

Panitumumab (0,0)
|
|

Pentostatin
(0,1)
|
|

Platinum compounds
(3,0)
|
|

Porfimer sodium and temoporfin
(0,2)
|
|

Procarbazine
(1,0)
|
|

Protein kinase inhibitors
(22,1)
|
|

Taxanes
(4,0)
|
|

Topoisomerase I inhibitors
(2,0)
|
|

Trabectedin
(1,0)
|
|

Trastuzumab
(3,0)
|
|

Tretinoin
(1,0)
|
|

Vismodegib
(0,1)
|
08.02 |
Drugs affecting the immune response
(1,0)
|
|

Immunosuppressant therapy (0,0)
|
08.02.01 |
Antiproliferative immunosuppressants
(3,0)
|
08.02.02 |
Corticosteroids and other immunosuppressants
(8,6)
|
08.02.03 |
Anti-lymphocyte monoclonal antibodies
(4,0)
|
08.02.04 |
Other immunomodulating drugs
(13,5)
|
|

Interferon Alfa
(3,0)
|
|

Interferon beta
(3,0)
|
|

Aldesleukin
(0,1)
|
|

Glatiramer acetate
(1,0)
|
|

Natalizumab
(1,0)
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
08.03.01 |
Oestrogens
(1,1)
|
08.03.02 |
Progestogens
(3,0)
|
08.03.03 |
Androgens (0,0)
|
08.03.04 |
Hormone antagonists (0,0)
|
08.03.04.01 |
Breast cancer
(8,1)
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues (0,0)
|
|

Gonadorelin analogues
(1,1)
|
|

Anti-androgens
(9,0)
|
08.03.04.03 |
Somatostatin analogues
(4,0)
|
|
|
|